Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Active-controlled Trial to Assess the Safety and Pharmacodynamics of Two Blinded Doses of Vortosiran and Open-label Apixaban in Patients With Non-valvular Atrial Fibrillation (AF)

NCT07870889 is registered in ClinicalTrials.gov with Ribocure Pharmaceuticals AB as lead sponsor.

NCT NCT07870889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07870889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Active-controlled Trial to Assess the Safety and Pharmacodynamics of Two Blinded Doses of Vortosiran and Open-label Apixaban in Patients With Non-valvular Atrial Fibrillation (AF)
Lead sponsor
Ribocure Pharmaceuticals AB
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
August 31, 2028
Enrollment
150 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

non-valvular atrial fibrillation (af)